Home › Trial NCT07554521
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
- Trial IDNCT07554521
- StatusRecruiting
- PhasePhase 2
- Study typeInterventional
- SponsorBeOne Medicines
- Enrollment30
- Start date2026-04-30
- ConditionsAdvanced Unresectable Gastric Adenocarcinoma · Esophageal Squamous Cell Carcinoma · Advanced Gastroesophageal Adenocarcinoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.